Tokyo Tape
Sign in

Carna Biosciences

4572.TTSE GROWTHPharmaceutical
Financials · Consolidated
ConsolidatedStandalone
Fiscal year ended2025-122024-122023-122022-122021-122020-12
Revenue¥579m¥636m¥1.6bn¥1.4bn¥2.0bn¥1.1bn
Operating income−¥2.1bn−¥2.1bn−¥1.1bn−¥1.3bn−¥531m—
Ordinary income−¥2.1bn−¥2.1bn−¥1.1bn−¥1.3bn−¥523m−¥1.1bn
Net income (owners)−¥2.2bn−¥2.2bn−¥1.2bn−¥1.3bn−¥534m−¥1.1bn
Total assets¥1.2bn¥2.8bn¥4.3bn¥4.3bn¥5.4bn¥4.8bn
Net assets / equity¥309m¥2.5bn¥3.9bn¥3.6bn¥4.3bn¥3.8bn
Operating cash flow−¥2.2bn−¥1.4bn−¥1.7bn−¥708m−¥1.5bn−¥1.3bn
EPS (basic)¥-113.62¥-121.64¥-68.62¥-99.1¥-42.1¥-90.33

From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.

Reports · 13
AllAnnual 4Half-year 3Quarterly 620262025202420232022
PeriodFormFiledFigures
2026-01-01 → 2026-06-30Half-year2026-08-0771 figures · EDINET
2025-01-01 → 2025-12-31Annual2026-03-26188 figures · EDINET
2025-01-01 → 2025-06-30Half-year2025-08-0771 figures · EDINET
2024-01-01 → 2024-12-31Annual2025-03-26188 figures · EDINET
2024-01-01 → 2024-06-30Half-year2024-08-0871 figures · EDINET
2024-01-01 → 2024-03-31Quarterly Q12024-05-1347 figures · EDINET
2023-01-01 → 2023-12-31Annual2024-03-27192 figures · EDINET
2023-01-01 → 2023-09-30Quarterly Q32023-11-0849 figures · EDINET
2023-01-01 → 2023-06-30Quarterly Q22023-08-0873 figures · EDINET
2023-01-01 → 2023-03-31Quarterly Q12023-05-1147 figures · EDINET
2022-01-01 → 2022-12-31Annual2023-03-27192 figures · EDINET
2022-01-01 → 2022-09-30Quarterly Q32022-11-0849 figures · EDINET
2022-01-01 → 2022-06-30Quarterly Q22022-08-0873 figures · EDINET

22 more reports are still being processed.

Segments · FY ended 2025-12
SegmentExternal salesProfitAssets
Drug Discovery Business—−¥2.0bn¥313m
Drug Discovery Support Business¥579m−¥51m¥388m
Adjustments & eliminations——¥528m
Total¥579m−¥2.1bn¥701m

Segment names from EDINET member IDs; not mapped to a common taxonomy.